跳至主要内容
临床试验/EUCTR2014-001856-51-DK
EUCTR2014-001856-51-DK进行中(未招募)1 期

Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial

Aleksander Krag0 个研究点目标入组 136 人开始时间: 2014年6月10日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
136

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Liver fibrosis estimated by an Ishak score from 1-4
  • 2. Women of child-bearing potential should use safe anti-conception and provide a negative pregnancy test.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 120
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 16

排除标准

  • 1. Known allergy to rifaximin
  • 2. The investigator judge that the patient would not be compliant with trial medicine
  • 3. Antibiotic treatment the prior 4 weeks

研究者

发起方
Aleksander Krag

相似试验